Freenome
Freenome is a biotechnology company developing multiomics blood-based cancer screening tests that combine genomic, epigenomic, and proteomic biomarkers with machine learning to detect cancer in early, treatable stages.
Public Company
Freenome is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2014
Employees
501–1,000
Total Funding
$1.48B
10 rounds
Last Private Valuation
$3.15B
Feb 15, 2024
Secondary Signals (Note: SetterVC does not verify the accuracy of these)
4 signalsFDA approved SimpleScreen CRC blood test; triggers $100M Abbott milestone payment, exclusive US commercialization.
Non-dilutive cash inflow and commercial-stage validation ahead of fall 2026 launch.
Closed SPAC business combination with Perceptive Capital Solutions Corp, began trading on Nasdaq as FRNM.
Converts private holdings to public, listed liquidity.
Closed SPAC merger with Perceptive Capital Solutions with $240M PIPE and ~$310M gross proceeds; trades on Nasdaq as FRNM
Now publicly traded; private secondary pricing superseded by FRNM market price
Roche agreed to $75M equity investment in Freenome alongside ex-US rights to multiomic cancer screening; Exact Sciences commercialization deal also in place
Strategic validation alongside SPAC; supports floor on revised valuation
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $1.48B across 10 rounds
Last updated 10-08-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Nov 18, 2025 | Strategic — Roche (convertible note) Press release | $75M | — | Roche |
| Aug 12, 2025 | Strategic — Exact Sciences (convertible note) | $50M | — | Exact Sciences |
| Feb 15, 2024 | Series E | $254M | $3.15B | Roche |
Valuation Trajectory
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Entry · Series A
$1B
Mar 2017
Freenome today
$3.1B
Feb 2024 · latest mark
Freenome multiple
3.1x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Prominent Investors
Leadership
Aaron Elliott
Chief Executive Officer
Riley Ennis
Co-Founder and Chief Product Officer
Linh H. Le
Chief Financial Officer
Jimmy Lin
Chief Scientific Officer
Robert Guigley
Chief Commercial Officer
Thomas Fitzpatrick
Chief Legal Officer
Julie Tran
Chief People Officer
Sally Howard
Senior Vice President, Regulatory and Quality
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Exact Sciences
Molecular diagnostics company with broad cancer screening portfolio; acquired exclusive U.S. rights to Freenome's colorectal cancer test for $75M in 2025
GRAIL (Illumina subsidiary)
Develops Galleri, a multi-cancer early detection blood test; received breakthrough device designation
Guardant Health
Develops Shield blood-based colorectal cancer screening test; received FDA clearance in mid-2024
Verily Life Sciences
Alphabet subsidiary developing cancer detection and screening technologies; early investor in Freenome
Freenome Investment FAQ
Freenome FAQ
Freenome completed its business combination with Perceptive Capital Solutions Corp on 2026-07-20 and now trades on the Nasdaq Capital Market under the ticker FRNM, having taken in roughly $310.3 million of gross proceeds — $70.3 million released from the SPAC trust and a $240.0 million PIPE led by Perceptive Advisors and RA Capital. The transaction, agreed in December 2025, valued the company at a target of about $1.1 billion, a substantial step down from its last private mark. Roche converted a $75 million note at closing and holds about 17.4 percent of the listed company.
Freenome shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Freenome had a valuation of approximately $3.15B at the time of its public offering. Current market capitalization fluctuates with the share price.
Freenome raised $1.48B across 10 disclosed funding rounds prior to its public listing.
Freenome was founded by Riley Ennis in 2014.
Freenome is headquartered in Brisbane, California.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.